10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

Outcomes data for a durable-polymer everolimus-eluting stent (EES) at extended long-term follow-up in patients with ST-segment elevation myocardial infarction (STEMI) are unknown. The aim of this study was to assess the 10-year outcomes enrolled EXAMINATION (A Clinical Evaluation Everolimus Eluting Coronary Stents Treatment Patients With ST-Segment Elevation Myocardial Infarction) trial. EXAMINATION-EXTEND (10-Years Follow-Up Trial) is an investigator-driven trial, which randomly assigned 1,498 STEMI 1:1 ratio receive either EES (n = 751) or bare-metal stents 747). primary endpoint patient-oriented composite all-cause death, any infarction, revascularization. Secondary endpoints included device-oriented cardiac target vessel lesion revascularization; individual components combined endpoints; and thrombosis. Complete clinical obtained 94.5% group 95.9% group. Rates were significantly reduced (32.4% vs. 38.0% [hazard ratio: 0.81; 95% confidence interval: 0.68 0.96; p 0.013] 13.6% 18.4% 0.72; 0.55 0.93; 0.012], respectively), driven mainly by revascularization (5.7% 8.8%; 0.018). rate definite thrombosis similar both groups (2.2% 2.5%; 0.590). No differences found between terms (1.4% 1.3%; 0.963) probable (0.6% 0.4%; 0.703) 5 10 years. At follow-up, demonstrated confirmed superiority patient- compared requiring percutaneous coronary intervention. Between 5- low incidence adverse cardiovascular events related device failure groups. Trial; NCT04462315 )